443 related articles for article (PubMed ID: 7540727)
1. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population.
Lee SP; Morgan S; Skinner J; Thomas WA; Jones SR; Sutton J; Khanna R; Whittle HC; Rickinson AB
Eur J Immunol; 1995 Jan; 25(1):102-10. PubMed ID: 7531142
[TBL] [Abstract][Full Text] [Related]
3. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
4. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
Gavioli R; Kurilla MG; de Campos-Lima PO; Wallace LE; Dolcetti R; Murray RJ; Rickinson AB; Masucci MG
J Virol; 1993 Mar; 67(3):1572-8. PubMed ID: 7679748
[TBL] [Abstract][Full Text] [Related]
5. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.
Levitsky V; Zhang QJ; Levitskaya J; Kurilla MG; Masucci MG
J Immunol; 1997 Dec; 159(11):5383-90. PubMed ID: 9548478
[TBL] [Abstract][Full Text] [Related]
6. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
8. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
11. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
12. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.
de Campos-Lima PO; Levitsky V; Brooks J; Lee SP; Hu LF; Rickinson AB; Masucci MG
J Exp Med; 1994 Apr; 179(4):1297-305. PubMed ID: 7511684
[TBL] [Abstract][Full Text] [Related]
13. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
[TBL] [Abstract][Full Text] [Related]
14. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus.
Zaldumbide A; Ossevoort M; Wiertz EJ; Hoeben RC
Mol Immunol; 2007 Feb; 44(6):1352-60. PubMed ID: 16828498
[TBL] [Abstract][Full Text] [Related]
15. Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein.
Fu TM; Bonneau RH; Epler M; Tevethia MJ; Alam S; Verner K; Tevethia SS
Virology; 1996 Aug; 222(1):269-74. PubMed ID: 8806508
[TBL] [Abstract][Full Text] [Related]
16. Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T-cell recognition.
Bu D; Domenech N; Lewis J; Taylor-Papadimitriou J; Finn OJ
J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):127-35. PubMed ID: 7506575
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
18. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
19. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
